Shohat-Tal, Aya
Sen, Aritro
Barad, David H.
Kushnir, Vitaly A.
Gleicher, Norbert
Article History
First Online: 14 July 2015
Competing interests
: N.G. and D.H.B. are listed as co-inventors on four awarded US patents, which claim therapeutic benefits of DHEA and other androgens in women with low functional ovarian reserve (US 7,615,544: 'Method of improving cumulative embryo score and quantity of fertilized oocytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone'; US 8,067,400: 'Androgen treatment in females'; US 8,501,719: 'Androgen treatment in females'; and US 8,501,718: 'Androgen treatment in females'). N.G. and D.H.B. are also listed as co-inventors on two awarded US patents, which are not related to the subject of this Review (US 8,629,120: 'Method of treatment related to the FMR1 gene'; and US 8,951,724: 'Detection of infertility risk and premature ovarian aging, addressing various claimed effects and diagnostic functions of the FMR1 gene on ovaries and female fertility'). N.G. owns shares in Fertility Nutraceuticals, a company that sells DHEA products, and both N.G. and D.H.B. receive patent royalties from this company. N.G. is also the owner of The Centre for Human Reproduction, New York, NY, USA. A.S.-T., A.S. and V.A.K. declare no competing interests.